Olympiad Research LP Invests $252,000 in Thermo Fisher Scientific Inc. (NYSE:TMO)

Olympiad Research LP purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 484 shares of the medical research company’s stock, valued at approximately $252,000.

A number of other large investors have also made changes to their positions in TMO. Callan Capital LLC lifted its position in Thermo Fisher Scientific by 2.7% in the fourth quarter. Callan Capital LLC now owns 773 shares of the medical research company’s stock worth $402,000 after purchasing an additional 20 shares during the period. Prentice Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 7.2% during the 4th quarter. Prentice Wealth Management LLC now owns 1,040 shares of the medical research company’s stock worth $541,000 after acquiring an additional 70 shares during the period. Bell Bank boosted its position in shares of Thermo Fisher Scientific by 3.7% during the 4th quarter. Bell Bank now owns 1,789 shares of the medical research company’s stock valued at $931,000 after acquiring an additional 63 shares in the last quarter. Greystone Financial Group LLC lifted its stake in Thermo Fisher Scientific by 14.7% during the fourth quarter. Greystone Financial Group LLC now owns 3,700 shares of the medical research company’s stock worth $1,925,000 after purchasing an additional 473 shares during the period. Finally, Drum Hill Capital LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $338,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Royal Bank of Canada set a $693.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 31st. Wells Fargo & Company lifted their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Citigroup raised their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a research note on Friday, January 31st. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Finally, Bank of America dropped their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $656.86.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $532.55 on Monday. The stock’s 50-day moving average is $548.47 and its 200-day moving average is $567.32. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The firm has a market cap of $203.70 billion, a price-to-earnings ratio of 32.22, a price-to-earnings-growth ratio of 2.99 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.32%. Thermo Fisher Scientific’s payout ratio is 10.41%.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,125 shares of company stock valued at $11,231,699. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.